Patents by Inventor Anne Husebekk

Anne Husebekk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11725063
    Abstract: Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 15, 2023
    Assignee: Rallybio IPA, LLC
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Publication number: 20210189005
    Abstract: Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Patent number: 10882919
    Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 5, 2021
    Assignee: Rallybio IPA, LLC
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Patent number: 9834613
    Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible pregnancy.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 5, 2017
    Assignee: PROPHYLIX PHARMA AS
    Inventors: Bjorn Skogen, Anne Husebekk, Mette Kjaer, Jens Kjeldsen-Kragh
  • Publication number: 20170121422
    Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Application
    Filed: March 31, 2015
    Publication date: May 4, 2017
    Applicants: UNIVERSITETET I TROMSO - NORGES ARKTISKE UNIVERSIT ET, UNIVERSITY HOSPITAL OF NORTH NORWAY, NORINNOVA TECHNOLOGY TRANSFER AS
    Inventors: Terje MICHAELSEN, Oistein IHLE, Tor Brynjar STUGE, Anne HUSEBEKK, Heidi TILLER, Mariana EKSTEEN, Bjorn Ragnar SKOGEN
  • Publication number: 20160215062
    Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible pregnancy.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 28, 2016
    Applicant: PROPHYLIX PHARMA AS
    Inventors: Bjorn SKOGEN, Anne HUSEBEKK, Mette KJAER, Jens KJELDSEN-KRAGH
  • Publication number: 20140377283
    Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Inventors: Bjorn SKOGEN, Anne HUSEBEKK, Mette Kjaer KILLIE, Jens KJELDSEN-KRAGH
  • Publication number: 20110293633
    Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible pregnancy
    Type: Application
    Filed: January 5, 2006
    Publication date: December 1, 2011
    Applicant: TTO NORD AS
    Inventors: Bjørn Skogen, Anne Husebekk, Mette Kjeer Killje, Jens Kjeldsen-Kragh